Hoth Therapeutics, Inc. announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. He been at the university for 22 years, including his graduate and post-doctoral work through his current tenured faculty position in Neurology.

During his graduate work he developed an in vivo microdialysis technique that for the first time measured Alzheimer's-related proteins in a living animals in real-time over several days. He did seminal work to understand how the amyloid-beta peptide is regulated in the brain; both the peptide's production and clearance from the brain. In addition to his research laboratory, John is also Director of the Hope Center In Vivo Microdialysis Core Facility at Washington University that uses microdialysis to assist other groups, both academic and corporate, to assess their compounds on AD-related proteins in mice.

She is Co-Director of the Animal Behavior Core at the university where she focuses on assessment of cognitive and behavioral function in models of neurodegenerative disorders.